🌍·12h agoIndustry
Foundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.
Publisher
E
Eli Lilly
US
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investor.lilly.com
Leave the platform to read the original full article on the publisher site.
Source: Eli Lilly
Scope: Industry
Related coverage
More related coverage
Eli Lilly·23h ago
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
Novartis·1d ago
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Orion Corporation·1d ago
Orion’s production processes in Turku, Finland to become carbon free with new steam plant4/9/2026 Sustainability
Orion has commissioned a new steam plant at its Turku factory, as a result of which the site's pharm...
Merck (MSD) News·1d ago
Cardiometabolic and respiratory diseases
We have a long history of making an impact on diseases that affect the heart and lungs.